Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 7/2001

01-07-2001

H2O2 impairs inflammatory mediator release from immunologically stimulated RBL-2H3 cells through a redox-sensitive, calcium-dependent mechanism

Authors: C. Guérin-Marchand, H. Sénéchal, C. Pelletier, H. Fohrer, R. Olivier, B. David, B. Berthon, U. Blank

Published in: Inflammation Research | Issue 7/2001

Login to get access
Metadata
Title
H2O2 impairs inflammatory mediator release from immunologically stimulated RBL-2H3 cells through a redox-sensitive, calcium-dependent mechanism
Authors
C. Guérin-Marchand
H. Sénéchal
C. Pelletier
H. Fohrer
R. Olivier
B. David
B. Berthon
U. Blank
Publication date
01-07-2001
Publisher
Birkhäuser Verlag
Published in
Inflammation Research / Issue 7/2001
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/PL00000254

Other articles of this Issue 7/2001

Inflammation Research 7/2001 Go to the issue

OriginalPaper

Immunohistopathological appearance of three different types of injury in human skin

OriginalPaper

Targets of glucocorticoid action on TNF-α release by macrophages

OriginalPaper

Decreased expression of P-glycoprotein in interleukin-1β and interleukin-6 treated rat hepatocytes

OriginalPaper

Human umbilical cord blood monocyte-derived eosinophils produce superoxide but not nitric oxide

OriginalPaper

Anti-inflammatory planar chiral [2.2]paracyclophaneacetic acid enantiomers

OriginalPaper

IL-1 activates two phospholipid signaling pathways in intestinal epithelial cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits